Erasca, Inc. (ERAS)

US — Healthcare Sector
Peers: LYEL  CGEM  GLUE  RVMD  IPSC  TCRX  DSGN 

Automate Your Wheel Strategy on ERAS

With Tiblio's Option Bot, you can configure your own wheel strategy including ERAS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ERAS
  • Rev/Share 0.0
  • Book/Share 1.4104
  • PB 1.2124
  • Debt/Equity 0.1272
  • CurrentRatio 12.352
  • ROIC -0.3394

 

  • MktCap 484420770.0
  • FreeCF/Share -0.3806
  • PFCF -4.4928
  • PE -3.0735
  • Debt/Assets 0.1078
  • DivYield 0
  • ROE -0.3656

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 4
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation ERAS Raymond James -- Outperform -- $5 March 26, 2025

News

Erasca, Inc.: Carving A Different Niche In RAS Signaling
ERAS
Published: April 25, 2025 by: Seeking Alpha
Sentiment: Positive

Erasca, Inc. focuses on developing novel targeted therapies for solid tumors, particularly through the RAS/MAP kinase pathway, with a promising yet early-stage pipeline. The company's lead program, naporafenib, shows preliminary efficacy in NRAS-mutant melanoma, with key phase 3 data expected in 2025. Financially stable with a cash runway into at least 2027, Erasca can advance its pipeline without immediate funding concerns, mitigating dilution risk.

Read More
image for news Erasca, Inc.: Carving A Different Niche In RAS Signaling

About Erasca, Inc. (ERAS)

  • IPO Date 2021-07-16
  • Website https://www.erasca.com
  • Industry Biotechnology
  • CEO Jonathan E. Lim
  • Employees 103
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.